<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260504</url>
  </required_header>
  <id_info>
    <org_study_id>9611</org_study_id>
    <secondary_id>NCI-2017-01416</secondary_id>
    <secondary_id>RG1717068</secondary_id>
    <nct_id>NCT03260504</nct_id>
  </id_info>
  <brief_title>Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of aldesleukin when given together&#xD;
      with pembrolizumab in treating patients with kidney cancer that has spread to other parts of&#xD;
      the body. Aldesleukin may stimulate white blood cells to kill kidney cancer cells.&#xD;
      Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune&#xD;
      system attack the cancer, and may interfere with the ability of tumor cells to avoid&#xD;
      recognition by immune cells. Giving aldesleukin and pembrolizumab may work better in treating&#xD;
      patients with kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the safety and tolerability of aldesleukin (IL-2) combined with pembrolizumab&#xD;
      (MK-3475) in patients with metastatic clear cell renal cell carcinoma (RCC).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess preliminary antitumor activity of pembrolizumab in combination with IL-2.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To investigate the association of PD-L1 protein expression by pretreatment tumor with&#xD;
      response to treatment.&#xD;
&#xD;
      II. To investigate the association of regulatory T cell (Treg) frequency and Treg to effector&#xD;
      T cell (Teff) ratios in peripheral blood and tumor tissue with response to therapy.&#xD;
&#xD;
      III. To investigate the association of de novo serological and cellular responses against the&#xD;
      ubiquitous RCC tumor antigen 5T4 with response to therapy.&#xD;
&#xD;
      IV. To investigate the association of tumor infiltrating lymphocyte (TIL) repertoire&#xD;
      clonality with response to therapy and to assess the detection of dominant TIL clones within&#xD;
      peripheral blood over time in responding patients.&#xD;
&#xD;
      V. To investigate the association of whole genome copy number alterations measured on&#xD;
      pretreatment archived, formalin fixed, paraffin embedded (FFPE) tumor with response to&#xD;
      therapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of aldesleukin.&#xD;
&#xD;
      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also&#xD;
      receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on&#xD;
      days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4&#xD;
      cycles per treatment course in the absence of clinical disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up via surveillance scans for&#xD;
      every 3 months for up to 1 year or until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">December 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Duration of study participation and Surveillance Follow up.</time_frame>
    <description>Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>At baseline and every 3 months</time_frame>
    <description>Tumor imaging post-treatment compared to baseline imaging; assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>At baseline and every 3 months</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>At baseline and every 3 months</time_frame>
    <description>Assessed by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>At baseline and every 3 months</time_frame>
    <description>PFS will be evaluated using the method of Kaplan-Meier. Median PFS times and associated 95% confidence interval will also be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in performance status</measure>
    <time_frame>Duration of study participation and Surveillance Follow up.</time_frame>
    <description>Assessed by Eastern Cooperative Oncology Group (ECOG) Performance Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>Will be assessed by immunohistochemistry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute numbers of regulatory T cells (Treg)</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>Will assess the ratio of Treg and effector T cells. Analyses of T cell subsets will be correlated with clinical outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute numbers of effector T cells (Teff)</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>Will assess the ratio of Treg and Teff. Analyses of T cell subsets will be correlated with clinical outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>De novo 5T4 specific humoral and/or cellular immune responses</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>Will be analyzed as a potential marker of &quot;on target&quot; effective anti-tumor immunity and correlated with clinical response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor infiltrating lymphocytes (TIL) clonality score</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>TIL clonality score will be correlated with clinical outcomes of renal cell carcinoma (RCC) patients treated with IL-2 plus pembrolizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Chromosomal copy number alterations</measure>
    <time_frame>Retrospective after completion of enrollment</time_frame>
    <description>OncoScan chromosomal array analyses will be carried out on archived tumor for RCC patients treated with IL-2 and pembrolizumab and chromosomal numerical abnormalities (CNAs) correlated to objective response rate.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Stage III Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab, aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given SC or IV</description>
    <arm_group_label>Treatment (pembrolizumab, aldesleukin)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aldesleukin)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial&#xD;
&#xD;
          -  Have histologic confirmation of RCC with a clear cell component&#xD;
&#xD;
          -  Have advanced (not amenable to potentially curative surgery) or metastatic RCC&#xD;
&#xD;
          -  Available tissue from an archival tissue sample or newly obtained core or excisional&#xD;
             biopsy of a tumor lesion&#xD;
&#xD;
          -  May have received previous systemic treatments or regimens for metastatic RCC. Prior&#xD;
             therapy can include checkpoint blocking antibodies targeting PD-1, PD-L1, or cytotoxic&#xD;
             T lymphocyte-associated antigen-4 (CTLA-4) and/or targeted agents including TKIs, mTOR&#xD;
             inhibitors, or bevacizumab. Patients may choose to receive study treatment as their&#xD;
             initial therapy&#xD;
&#xD;
          -  Previously treated patients must have documented disease progression after their last&#xD;
             line of therapy&#xD;
&#xD;
          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance scale&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500 /mcL (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL or &gt;= 5.6 mmol/L (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 X upper limit of normal (ULN) OR measured or calculated&#xD;
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of&#xD;
             creatinine or CrCl) &gt;= 40 mL/min for subject with creatinine levels &gt; 1.5 X&#xD;
             institutional ULN; creatinine clearance should be calculated by Cockcroft-Gault&#xD;
             (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 X ULN OR direct bilirubin =&lt; ULN for subjects with total&#xD;
             bilirubin levels &gt; 1.5 ULN (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt; 2.5 X&#xD;
             ULN OR =&lt; 5 X ULN for subjects with liver metastases (within 14 days of treatment&#xD;
             initiation)&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 X ULN unless&#xD;
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin&#xD;
             time (PTT) is within therapeutic range of intended use of anticoagulants (within 14&#xD;
             days of treatment initiation)&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) =&lt; 1.5 X ULN unless subject is receiving&#xD;
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use&#xD;
             of anticoagulants (within 14 days of treatment initiation)&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) &gt;= 65% of&#xD;
             predicted (dose level 2 and 3)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50% measured by multigated acquisition&#xD;
             (MUGA) scan, echo, or stress test study with myocardial perfusion imaging&#xD;
&#xD;
          -  Normal/negative cardiac stress testing with myocardial perfusion imaging OR cardiac&#xD;
             catheterization with non-significant angiogram findings reviewed by a cardiology&#xD;
             consultant (dose level 2 and 3)&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy test within 72 hours prior to receiving the first dose of study medication;&#xD;
             if the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication; subjects of&#xD;
             childbearing potential are those who have not been surgically sterilized or have not&#xD;
             been free from menses for &gt; 1 year&#xD;
&#xD;
          -  Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received prior therapy with IL-2 or other investigational systemic cytokine&#xD;
             therapy signaling through a common Î³-chain cytokine receptor including IL-7, IL-15 or&#xD;
             IL-21&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or using an investigational device within 4 weeks of the first dose of treatment&#xD;
&#xD;
          -  Has had a prior monoclonal antibody within 4 weeks prior to study day 1. Has had prior&#xD;
             chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks&#xD;
             prior to study day 1&#xD;
&#xD;
          -  Adverse events due to prior treatment must be resolved to &lt; grade 1&#xD;
&#xD;
             * Note: If subject received major surgery, they must have recovered adequately from&#xD;
             the toxicity and/or complications from the intervention prior to starting therapy&#xD;
&#xD;
          -  For patients previously treated with checkpoint blocking antibodies, no history of&#xD;
             myocarditis, pneumonitis or nephritis of any grade associated with the prior treatment&#xD;
&#xD;
          -  Has had autoimmune toxicity associated with prior checkpoint blocking antibodies&#xD;
             requiring more than one drug class of immune suppressive therapy to resolve (e.g.&#xD;
             steroid-refractory toxicity requiring infliximab, mycophenolate mofetil, tacrolimus or&#xD;
             other immune suppressive agent) or requiring continuous immune suppression &gt; 12 weeks,&#xD;
             or having a severity judged to be life threatening by the investigator&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment;&#xD;
             exceptions include locally curable cancers such as basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ&#xD;
             of the cervix or breast that has undergone potentially curative therapy&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
               -  (Dose level 1) subjects with previously treated brain metastases may participate&#xD;
                  provided they are stable (without evidence of progression by imaging for at least&#xD;
                  four weeks prior to the first dose of trial treatment and any neurologic symptoms&#xD;
                  have returned to baseline), have no evidence of new or enlarging brain&#xD;
                  metastases, and are not using steroids for at least 7 days prior to trial&#xD;
                  treatment&#xD;
&#xD;
               -  (Dose Level 2 and 3) subjects may not have any history of or current CNS&#xD;
                  metastases; baseline imaging of the brain is required within 28 days prior to the&#xD;
                  start of study treatments&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment&#xD;
&#xD;
          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents; subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule; subjects that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study; subjects with hypothyroidism stable on hormone replacement or&#xD;
             Sjorgen's syndrome will not be excluded from the study&#xD;
&#xD;
          -  Has history of (non-infectious) pneumonitis that required steroids or active,&#xD;
             non-infectious pneumonitis&#xD;
&#xD;
          -  Ongoing symptomatic cardiac dysrhythmias, uncontrolled atrial fibrillation, or&#xD;
             prolongation of the corrected QT interval defined as &gt; 450 msec for males and &gt; 470&#xD;
             msec for female&#xD;
&#xD;
          -  History of any of the following cardiovascular conditions within 6 months of&#xD;
             enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina,&#xD;
             coronary artery bypass graft surgery, class III or IV congestive heart failure as&#xD;
             defined by the New York Heart Association, symptomatic peripheral vascular disease,&#xD;
             cerebrovascular accident, or transient ischemic attack&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)&#xD;
&#xD;
          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or&#xD;
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is&#xD;
             detected)&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment;&#xD;
             Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines&#xD;
             and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live&#xD;
             attenuated vaccines, and are not allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott S. Tykodi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott S. Tykodi</last_name>
    <phone>206-606-7763</phone>
    <email>stykodi@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott S. Tykodi</last_name>
      <phone>206-606-7763</phone>
      <email>stykodi@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Scott S. Tykodi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

